Literature DB >> 19710548

Impact of comorbidities on the management of psoriasis.

S Gerdes, U Mrowietz.   

Abstract

Psoriasis is associated with numerous comorbidities that have a major impact on severely affected patients. Besides psoriatic arthritis, other diseases such as metabolic syndrome and cardiovascular diseases are becoming of major importance. In particular, patients with severe forms of psoriasis are at a higher risk of developing cardiovascular diseases and myocardial infarction. In a recent study, a reduction in life expectancy was shown for this subgroup of patients. An increased prevalence of concomitant diseases leads to an increased intake of concomitant medication; thus, it is easy for comorbidities and their treatments to interact with routinely used antipsoriatic therapies and complicate the management of severely affected patients. This patient subgroup has a strong need of sufficient treatment not only for their severe skin symptoms, but also for preventing the possible development of comorbidities and their long-term complications. As dermatologists are often one of the first and most often consulted health care specialists for patients with psoriasis, advanced knowledge of the comorbid state of these patients should influence clinical management and lead to new standards of care. This article will summarize the current knowledge on comorbidities in psoriasis and their impact on patient management. Copyright (c) 038\ S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19710548     DOI: 10.1159/000232302

Source DB:  PubMed          Journal:  Curr Probl Dermatol        ISSN: 1421-5721


  6 in total

Review 1.  Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Authors:  Melinda Liu; Yuan Yu M Huang; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 2.  [Comorbidities and psoriasis. Impact on clinical practice].

Authors:  S Gerdes; U Mrowietz
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

Review 3.  Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.

Authors:  Wolfgang Weger
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  Retinol Binding Protein 4 in Non Obese Psoriatic Cases.

Authors:  Ola Ahmed Bakry; Mohamed Abdel Moneim Shoeib; Iman Masoud Abdel Gayed; Amany Said El Menoufy
Journal:  J Clin Diagn Res       Date:  2016-08-01

5.  Psoriasis alters HDL composition and cholesterol efflux capacity.

Authors:  Michael Holzer; Peter Wolf; Sanja Curcic; Ruth Birner-Gruenberger; Wolfgang Weger; Martin Inzinger; Dalia El-Gamal; Christian Wadsack; Akos Heinemann; Gunther Marsche
Journal:  J Lipid Res       Date:  2012-05-30       Impact factor: 5.922

6.  Heterogeneity of response to biologic treatment: perspective for psoriasis.

Authors:  Emily Edson-Heredia; Kimberly L Sterling; Carlos I Alatorre; Gebra Cuyun Carter; Rosirene Paczkowski; Victoria Zarotsky; Tomoko Maeda-Chubachi
Journal:  J Invest Dermatol       Date:  2013-08-06       Impact factor: 8.551

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.